<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648660</url>
  </required_header>
  <id_info>
    <org_study_id>2032- 06/07</org_study_id>
    <nct_id>NCT01648660</nct_id>
  </id_info>
  <brief_title>Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)</brief_title>
  <official_title>Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients for Two More Years (LUTEGA 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of LUTEGA 2 is it to determine the long term effect (about 2 more years
      after LUTEGA 1, NCT00763659) of the supplementation with a fixed combination of
      lutein/zeaxanthin and omega-3- fatty acids in two different dosages on the optical density
      (OD) of macular pigment in patients with non- exudative age related maculopathy. The dosage
      groups are crossed after LUTEGA 1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LUTEGA 2 is a cross-over- study and the continue of LUTEGA 1. After one year of
      supplementation in randomized, placebo- controlled, double blind study (LUTEGA 1), the
      treatment arms are unblind to cross over the different dosage groups.

      The measurement of optical density of macular pigment (MPOD) uses the 1- wavelength
      reflection method recording reflection images at 480 nm by a fundus camera. The patients are
      followed up over two years in eight more visits (every three months) In addition to the MPOD-
      measurement each examination includes standardized visual acuity test (ETDRS), amsler- grid,
      slit lamp biomicroscopy, fundus photography (color and autofluorescence) and a blood sample
      (every six months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optical density of macular pigment</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Age Related Maculopathy</condition>
  <arm_group>
    <arm_group_label>D2x - D1x</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cross Over from double dosage to single dosage:
daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1x - D2x</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cross Over from double dosage to single dosage:
daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1x - D1x</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein/ Zeaxanthin + Omega- 3- Fatty Acids</intervention_name>
    <description>capsule with Lutein, Zeaxanthin, Omega-3-FA for two years</description>
    <arm_group_label>D2x - D1x</arm_group_label>
    <arm_group_label>D1x - D2x</arm_group_label>
    <arm_group_label>D1x - D1x</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All non- exudative forms of age related maculopathy

        Exclusion Criteria:

          -  Exudative age related maculopathy

          -  decrease opacity of ocular media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¼rgen Strobel, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Dawczynski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>January 9, 2013</last_update_submitted>
  <last_update_submitted_qc>January 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Jens Dawczynski</investigator_full_name>
    <investigator_title>Prof. Dr. med. Jens Dawczynski</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

